Novartis says in the article below: "Locametz is expected to be available to physicians and patients within weeks." I would assume Novartis would have all bases covered, from manufacture to distribution.
It is really troubling to see Telix directly compete with Novartis for imaging since Novartis is likely to take the lions share of the market (US, EU and AU). I wasn't aware Novartis were also applying for approval for an imaging agent until last week, so this is a new but very significant revelation to me. It would be good to get clarification from TLX about this approval.
Good luck to all.
https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer
- Forums
- ASX - By Stock
- TLX
- How low will it go?
How low will it go?, page-102
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$17.74 |
Change
0.300(1.72%) |
Mkt cap ! $5.936B |
Open | High | Low | Value | Volume |
$17.50 | $17.88 | $17.42 | $23.05M | 1.299M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3775 | $17.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.74 | 1499 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 17.720 |
1 | 550 | 17.710 |
1 | 1559 | 17.630 |
2 | 3000 | 17.500 |
2 | 850 | 17.400 |
Price($) | Vol. | No. |
---|---|---|
17.740 | 1499 | 1 |
17.840 | 439 | 1 |
17.850 | 1500 | 1 |
17.890 | 100 | 1 |
17.910 | 563 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |